1
Yale Medicine Dermatology - New Haven
Doctors Building
2 Church Street South, Fl 3rd Ste 305
New Haven, CT 06519
1 of 2
- Yale Medicine Dermatology - New HavenDoctors Building2 Church Street South, Fl 3rd Ste 305New Haven, CT 06519
- Yale Health Center55 Lock Street, Ste 3rd FloorNew Haven, CT 06511
Mary Tomayko, MD, PhD
Dermatology
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
Yes
Referral required
MD to MD Consult
Board Certified in
Dermatology
Titles
- Associate Professor of Dermatology and of Pathology
- Director Yale Immunobullous Clinic, Dermatology
- Director Dermatology Medical Student Education, Dermatology
Education & Training
- Postdoctoral FellowYale University School of Medicine (2005)
- ResidentYale University School of Medicine (2004)
- InternUniversity of Pennsylvania Hospital (2001)
- MDUniv. of Pennsylvania School of Medicine (2000)
- PhDUniv. of Pennsylvania School of Medicine (1998)
Additional Information
Board Certifications
- AB of Dermatology, Dermatology (2005, recertified: 2016)
Publications
- Hoffman V, White M, Yale M, Strong R, Tomayko M. LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study. Journal Of Investigative Dermatology 2024, 144: s150. DOI: 10.1016/j.jid.2024.06.1242.
- White M, Hoffman V, Yale M, Strong R, Tomayko M. Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. Journal Of The European Academy Of Dermatology And Venereology 2024 PMID: 38837452, DOI: 10.1111/jdv.20156.
- Tran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.
- Jackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.
- Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.
- Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.
- Hwang E, Tomayko M. COVID‐19 outcomes in patients with autoimmune blistering disease. British Journal Of Dermatology 2021, 185: 1048-1050. PMID: 34107059, PMCID: PMC8239772, DOI: 10.1111/bjd.20571.
- Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.
- RituximabGelhausen, J.R., Heffernan, M. P. and Tomayko, M.M. Chapter 30: Rituximab. In Comprehensive Dermatologic Drug Therapy, 4th Edition. Ed. S. E. Wolverton and J.J. Wu. 2020.
- Karaaslan S, Tomayko MM. A Niche for Plasma Cells: The Skin. Journal Of Investigative Dermatology 2019, 139: 2411-2414. PMID: 31753124, DOI: 10.1016/j.jid.2019.06.133.
- Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.
- Tomayko MM, Allman D. What B cell memories are made of. Current Opinion In Immunology 2019, 57: 58-64. PMID: 30861463, DOI: 10.1016/j.coi.2019.01.003.
- Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.
- Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.
- Sadanand S, Tomayko M. B Cell Biology. 2017, 97-119. DOI: 10.1007/978-3-319-29785-9_7.
- Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Reports 2016, 2: 442-444. PMID: 27981213, PMCID: PMC5144742, DOI: 10.1016/j.jdcr.2016.05.009.
- Waldman A, Ezaldein H, Tomayko M, Galan A. Nodular plaque in a cardiac transplant patient. Journal Of The American Academy Of Dermatology 2015, 72: e111-e112. DOI: 10.1016/j.jaad.2014.12.037.
- Haberland C, Johnson M, Tomayko M. Pemphigus vulgaris presenting as gingival hypertrophy in a child. Oral Surgery Oral Medicine Oral Pathology And Oral Radiology 2014, 118: e191. DOI: 10.1016/j.oooo.2014.05.088.
- Zuccarino-Catania GV, Sadanand S, Weisel FJ, Tomayko MM, Meng H, Kleinstein SH, Good-Jacobson KL, Shlomchik MJ. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nature Immunology 2014, 15: 631-637. PMID: 24880458, PMCID: PMC4105703, DOI: 10.1038/ni.2914.
- Conter LJ, Song E, Shlomchik MJ, Tomayko MM. CD73 Expression Is Dynamically Regulated in the Germinal Center and Bone Marrow Plasma Cells Are Diminished in Its Absence. PLOS ONE 2014, 9: e92009. PMID: 24664100, PMCID: PMC3963874, DOI: 10.1371/journal.pone.0092009.
- Tomayko MM, Steinel NC, Anderson SM, Shlomchik MJ. Cutting Edge: Hierarchy of Maturity of Murine Memory B Cell Subsets. The Journal Of Immunology 2010, 185: 7146-7150. PMID: 21078902, PMCID: PMC3133669, DOI: 10.4049/jimmunol.1002163.
- Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nature Immunology 2010, 11: 535-542. PMID: 20453843, PMCID: PMC2874069, DOI: 10.1038/ni.1877.
- Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ, Goenka R, Miller JP, Cho YH, Long V, Ward C, Migone TS, Shlomchik MJ, Cancro MP. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 15517-15522. PMID: 18832171, PMCID: PMC2563088, DOI: 10.1073/pnas.0807841105.
- Crowley J, Scholz J, Tomayko M, Steinel N, O'Neill P, Miller J, Cho Y, Long V, Ward C, Migone T, Shlomchik M, Cancro M. BLyS Neutralization Ablates Primary But Not Memory B Cell Pools. The FASEB Journal 2008, 22: 366-366. DOI: 10.1096/fasebj.22.2_supplement.366.
- Cancro M, Allman D, Hayes C, Lentz V, Fields R, Sah A, Tomayko M. B cell maturation and selection at the marrow-periphery interface. Immunologic Research 1998, 17: 3-11. PMID: 9479562, DOI: 10.1007/bf02786425.
- Tomayko M, Triche T, Reynolds C. Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. International Journal Of Developmental Neuroscience 1996, 14: 771-777. PMID: 8960984, DOI: 10.1016/s0736-5748(96)00050-0.
- Wada R, Seeger R, Brodeur G, Einhorn P, Rayner S, Tomayko M, Reynolds C. Human neuroblastoma cell lines that express N‐myc without gene amplification. Cancer 1993, 72: 3346-3354. PMID: 8242562, DOI: 10.1002/1097-0142(19931201)72:11<3346::aid-cncr2820721134>3.0.co;2-e.
- Tomayko M, Reynolds C. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy And Pharmacology 1989, 24: 148-154. PMID: 2544306, DOI: 10.1007/bf00300234.
- Cell Biology, in Clinical and Basic ImmunodermatologySadanand, SS and Tomayko, MM. B Cell Biology, in Clinical and Basic Immunodermatology, Eds. Kaplan DH, Gaspari, AA, Stingl, G. In press.
Departments and Programs
Locations
1
Yale Medicine Dermatology - New Haven
Doctors Building
2 Church Street South, Fl 3rd Ste 305
New Haven, CT 06519
1 of 2
- Yale Medicine Dermatology - New HavenDoctors Building2 Church Street South, Fl 3rd Ste 305New Haven, CT 06519
- Yale Health Center55 Lock Street, Ste 3rd FloorNew Haven, CT 06511
Titles
- Associate Professor of Dermatology and of Pathology
- Director Yale Immunobullous Clinic, Dermatology
- Director Dermatology Medical Student Education, Dermatology
Education & Training
- Postdoctoral FellowYale University School of Medicine (2005)
- ResidentYale University School of Medicine (2004)
- InternUniversity of Pennsylvania Hospital (2001)
- MDUniv. of Pennsylvania School of Medicine (2000)
- PhDUniv. of Pennsylvania School of Medicine (1998)
Additional Information
Board Certifications
- AB of Dermatology, Dermatology (2005, recertified: 2016)
Publications
- Hoffman V, White M, Yale M, Strong R, Tomayko M. LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study. Journal Of Investigative Dermatology 2024, 144: s150. DOI: 10.1016/j.jid.2024.06.1242.
- White M, Hoffman V, Yale M, Strong R, Tomayko M. Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. Journal Of The European Academy Of Dermatology And Venereology 2024 PMID: 38837452, DOI: 10.1111/jdv.20156.
- Tran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.
- Jackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.
- Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.
- Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.
- Hwang E, Tomayko M. COVID‐19 outcomes in patients with autoimmune blistering disease. British Journal Of Dermatology 2021, 185: 1048-1050. PMID: 34107059, PMCID: PMC8239772, DOI: 10.1111/bjd.20571.
- Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.
- RituximabGelhausen, J.R., Heffernan, M. P. and Tomayko, M.M. Chapter 30: Rituximab. In Comprehensive Dermatologic Drug Therapy, 4th Edition. Ed. S. E. Wolverton and J.J. Wu. 2020.
- Karaaslan S, Tomayko MM. A Niche for Plasma Cells: The Skin. Journal Of Investigative Dermatology 2019, 139: 2411-2414. PMID: 31753124, DOI: 10.1016/j.jid.2019.06.133.
- Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.
- Tomayko MM, Allman D. What B cell memories are made of. Current Opinion In Immunology 2019, 57: 58-64. PMID: 30861463, DOI: 10.1016/j.coi.2019.01.003.
- Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.
- Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.
- Sadanand S, Tomayko M. B Cell Biology. 2017, 97-119. DOI: 10.1007/978-3-319-29785-9_7.
- Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Reports 2016, 2: 442-444. PMID: 27981213, PMCID: PMC5144742, DOI: 10.1016/j.jdcr.2016.05.009.
- Waldman A, Ezaldein H, Tomayko M, Galan A. Nodular plaque in a cardiac transplant patient. Journal Of The American Academy Of Dermatology 2015, 72: e111-e112. DOI: 10.1016/j.jaad.2014.12.037.
- Haberland C, Johnson M, Tomayko M. Pemphigus vulgaris presenting as gingival hypertrophy in a child. Oral Surgery Oral Medicine Oral Pathology And Oral Radiology 2014, 118: e191. DOI: 10.1016/j.oooo.2014.05.088.
- Zuccarino-Catania GV, Sadanand S, Weisel FJ, Tomayko MM, Meng H, Kleinstein SH, Good-Jacobson KL, Shlomchik MJ. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nature Immunology 2014, 15: 631-637. PMID: 24880458, PMCID: PMC4105703, DOI: 10.1038/ni.2914.
- Conter LJ, Song E, Shlomchik MJ, Tomayko MM. CD73 Expression Is Dynamically Regulated in the Germinal Center and Bone Marrow Plasma Cells Are Diminished in Its Absence. PLOS ONE 2014, 9: e92009. PMID: 24664100, PMCID: PMC3963874, DOI: 10.1371/journal.pone.0092009.
- Tomayko MM, Steinel NC, Anderson SM, Shlomchik MJ. Cutting Edge: Hierarchy of Maturity of Murine Memory B Cell Subsets. The Journal Of Immunology 2010, 185: 7146-7150. PMID: 21078902, PMCID: PMC3133669, DOI: 10.4049/jimmunol.1002163.
- Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nature Immunology 2010, 11: 535-542. PMID: 20453843, PMCID: PMC2874069, DOI: 10.1038/ni.1877.
- Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ, Goenka R, Miller JP, Cho YH, Long V, Ward C, Migone TS, Shlomchik MJ, Cancro MP. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 15517-15522. PMID: 18832171, PMCID: PMC2563088, DOI: 10.1073/pnas.0807841105.
- Crowley J, Scholz J, Tomayko M, Steinel N, O'Neill P, Miller J, Cho Y, Long V, Ward C, Migone T, Shlomchik M, Cancro M. BLyS Neutralization Ablates Primary But Not Memory B Cell Pools. The FASEB Journal 2008, 22: 366-366. DOI: 10.1096/fasebj.22.2_supplement.366.
- Cancro M, Allman D, Hayes C, Lentz V, Fields R, Sah A, Tomayko M. B cell maturation and selection at the marrow-periphery interface. Immunologic Research 1998, 17: 3-11. PMID: 9479562, DOI: 10.1007/bf02786425.
- Tomayko M, Triche T, Reynolds C. Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. International Journal Of Developmental Neuroscience 1996, 14: 771-777. PMID: 8960984, DOI: 10.1016/s0736-5748(96)00050-0.
- Wada R, Seeger R, Brodeur G, Einhorn P, Rayner S, Tomayko M, Reynolds C. Human neuroblastoma cell lines that express N‐myc without gene amplification. Cancer 1993, 72: 3346-3354. PMID: 8242562, DOI: 10.1002/1097-0142(19931201)72:11<3346::aid-cncr2820721134>3.0.co;2-e.
- Tomayko M, Reynolds C. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy And Pharmacology 1989, 24: 148-154. PMID: 2544306, DOI: 10.1007/bf00300234.
- Cell Biology, in Clinical and Basic ImmunodermatologySadanand, SS and Tomayko, MM. B Cell Biology, in Clinical and Basic Immunodermatology, Eds. Kaplan DH, Gaspari, AA, Stingl, G. In press.
Departments and Programs
Locations
1
Yale Medicine Dermatology - New Haven
Doctors Building
2 Church Street South, Fl 3rd Ste 305
New Haven, CT 06519
1 of 2
- Yale Medicine Dermatology - New HavenDoctors Building2 Church Street South, Fl 3rd Ste 305New Haven, CT 06519
- Yale Health Center55 Lock Street, Ste 3rd FloorNew Haven, CT 06511
1
Yale Medicine Dermatology - New Haven
Doctors Building
2 Church Street South, Fl 3rd Ste 305
New Haven, CT 06519
1 of 2
- Yale Medicine Dermatology - New HavenDoctors Building2 Church Street South, Fl 3rd Ste 305New Haven, CT 06519
- Yale Health Center55 Lock Street, Ste 3rd FloorNew Haven, CT 06511